Artios Initiates P-II Randomized Trial of ART0380 + Gemcitabine for Platinum Resistant Ovarian Cancer
Shots:
- The company initiates the P-II expansion cohort from an ongoing P-I/II trial evaluating intermittent dosing of ART0380 as monotx. or in combination with gemcitabine. The study is expected to enroll ~60 patients at multiple oncology centers across the US & Spain
- The initial P-II study results are expected in H1’25. The P-I dose escalation study showed a favorable safety & tolerability profile, clinical activity, and preferred PK with ART0380 for advanced solid tumors
- ART0380 is a potent, selective, ATR inhibitor, a master regulator of DNA replication stress response & is being developed as an oral anti-cancer agent for cancers that harbor defects in DNA repair & in combination with agents incl. those that cause DNA damage
Ref: Artios | Image: Artios
Related News:- Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
